All Stories

  1. Poised for Innovation
  2. Steroid–tacrolimus drug–drug interaction and the effect of CYP3A genotypes
  3. No Time for Cancel Culture
  4. The prevalence of postacute sequelae of coronavirus disease 2019 in solid organ transplant recipients: Evaluation of risk in the National COVID Cohort Collaborative
  5. Comparing the prognostic performance of iBOX and biopsy-proven acute rejection for long-term kidney graft survival
  6. Prospective observational study to validate a next-generation sequencing blood RNA signature to predict early kidney transplant rejection
  7. The Banff 2022 Kidney Meeting Report: Reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnostics
  8. The Banff 2022 Kidney Meeting Work Plan: Data-driven refinement of the Banff Classification for renal allografts
  9. The Banff process—Reloaded: A joint initiative from the Banff Foundation for Allograft Pathology and the American Journal of Transplantation
  10. Impact of Centers for Medicare and Medicaid Services Final Rule on Organ Procurement Organization Metrics and Procedural Trends in the Procurement of Pancreata for Research
  11. Personalizing kidney transplant donor-specific antibody surveillance: The devil is in the details
  12. Hormone replacement therapy and COVID-19 outcomes in solid organ transplant recipients compared with the general population
  13. Tu1890 SOLID ORGAN TRANSPLANTATION CHANGES THE GUT MICROBIOME AND METAGENOME BUT THE METABOLOME IDENTIFIES METABOLIC SYNDROME POST TRANSPLANTATION
  14. Kidney Transplant Practice in Pandemic Times
  15. Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizers
  16. Solid Organ Transplantation: Rejection, Immunosuppression, and Tolerance
  17. The Gut Microbiome Links to Metabolic Syndrome Following Kidney Transplantation
  18. The risk and consequences of breakthrough SARS-CoV-2 infection in solid organ transplant recipients relative to non-immunosuppressed controls
  19. A multi-faceted approach to sex and gender equity in solid organ transplantation: The Women in Transplantation Initiative of The Transplantation Society
  20. Impact of CYP3A5 Status on the Clinical and Financial Outcomes Among African American Kidney Transplant Recipients
  21. 426.4: The Gut Microbiome Facilitates Metabolic Syndrome (MBS) Post Kidney Transplantation
  22. Data carve out in the midst of the COVID ‐19 pandemic
  23. Exacerbation of Racial Disparities in Living Donor Kidney Transplantation During the COVID-19 Pandemic
  24. Deceased Donor Procurement Biopsy Practices, Interpretation, and Histology-Based Decision-Making: A Survey of US Kidney Transplant Centers
  25. The Agony and the Ecstasy: Stories from Organ Transplant Recipients
  26. Abnormal time‐zero histology is predictive of kidney transplant outcomes
  27. Premature Death in Kidney Transplant Recipients: The Time for Trials is Now
  28. T cell–mediated rejection in kidney transplant recipients: The end(point) is also the beginning
  29. From the Cradle to the Grave: The Life Cycle of Gender Disparities in Kidney Care
  30. Sex and gender as predictors for allograft and patient-relevant outcomes after kidney transplantation
  31. Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US
  32. Understanding and Overcoming Financial Risks for Living Organ Donors
  33. Risk Prediction for Delayed Allograft Function: Analysis of the Deterioration of Kidney Allograft Function (DeKAF) Study Data
  34. Gut microbial biomarkers for predicting adverse outcomes in people with chronic kidney disease
  35. Disparities in Access to Preemptive Repeat Kidney Transplant: Still Missing the Mark?
  36. Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative
  37. Roslyn (“Roz”) Bernstein Mannon, MD
  38. Emerging biomarkers in kidney transplantation and challenge of clinical implementation
  39. Sex and organ‐specific risk of major adverse renal or cardiac events in solid organ transplant recipients with COVID‐19
  40. Operational challenges in the COVID‐19 era: Asymptomatic infections and vaccination timing
  41. Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data
  42. Significance of HLA-DQ in kidney transplantation: time to reevaluate human leukocyte antigen–matching priorities to improve transplant outcomes? An expert review and recommendations
  43. COVID-19 in Solid Organ Transplantation: Results of the National COVID Cohort Collaborative
  44. Time for increased awareness of sex as a biological variable in transplantation
  45. Incorporation of Sex and Gender Guidelines Into Transplantation Literature
  46. Bioenergetic maladaptation and release of HMGB1 in calcineurin inhibitor-mediated nephrotoxicity
  47. In Memoriam: Barbara T Murphy, MB, BAO, BCh (Hon), MRCIP, FRCPI
  48. Disparities in Deceased Organ Donor Research Authorization: Experience at One Organ Procurement Organization and Call for National Conversations
  49. Meeting Report: First State of the Art Meeting on Gender Disparity in Kidney Transplantation in the Asia-Pacific
  50. Novel Phenotypes for Acute Kidney Transplant Rejection Using Semi-supervised Clustering
  51. COVID-19 Disease Severity among People with HIV Infection or Solid Organ Transplant in the United States: A Nationally-representative, Multicenter, Observational Cohort Study
  52. Donor-Specific Antibody Is Associated with Increased Expression of Rejection Transcripts in Renal Transplant Biopsies Classified as No Rejection
  53. Banff and ABMR: Are we going in the right direction?
  54. Living Organ Donor Perspectives and Sources of Hesitancy about COVID-19 Vaccines
  55. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant
  56. Industry partnerships in transplantation: How should AJT manage the inevitable conflict of interest?
  57. i-IFTA and chronic active T cell–mediated rejection: A tale of 2 (DeKAF) cohorts
  58. Practicing With Uncertainty: Kidney Transplantation During the COVID-19 Pandemic
  59. Chronic Allograft Injury
  60. Dynamic Response of Donor-Derived Cell-Free DNA Following Treatment of Acute Rejection in Kidney Allografts
  61. COVID‐19 test result reporting for deceased donors: Emergent policies, logistical challenges, and future directions
  62. Sex matters: COVID-19 in kidney transplantation
  63. Precision Dosing for Tacrolimus Using Genotypes and Clinical Factors in Kidney Transplant Recipients of European Ancestry
  64. A glossary for patient care and scientific dialogue from KDIGO
  65. Impact of Subclinical Borderline Inflammation on Kidney Transplant Outcomes
  66. Avoidance of CNI and steroids using belatacept—Results of the Clinical Trials in Organ Transplantation 16 trial
  67. Avoiding surveillance biopsy: Use of a noninvasive biomarker assay in a real‐life scenario
  68. Survey of US Living Kidney Donation and Transplantation Practices in the COVID-19 Era
  69. Is It Time for Operation Warp Speed in Transplant Research?
  70. Sensitization in transplantation: Assessment of risk (STAR) 2019 Working Group Meeting Report
  71. The COVID‐19 pandemic: A community approach
  72. Apolipoprotein L1: role in the evaluation of kidney transplant donors
  73. Inflammation in areas of fibrosis: The DeKAF prospective cohort
  74. The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell– and antibody-mediated rejection
  75. Pharmacogenomics in kidney transplant recipients and potential for integration into practice
  76. Challenges of calcineurin inhibitor withdrawal following combined pancreas and kidney transplantation: Results of a prospective, randomized clinical trial
  77. The Advancing American Kidney Health (AAKH) Executive Order: Promise and Caveats for Expanding Access to Kidney Transplantation
  78. Use of biomarkers to improve immunosuppressive drug development and outcomes in renal organ transplantation: A meeting report
  79. Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group
  80. Use of Checkpoint Inhibitors in a Kidney Transplant Recipient with Metastatic Cancer
  81. APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO): Design and Rationale
  82. Redefining the Influence of Ethnicity on Simultaneous Kidney and Pancreas Transplantation Outcomes
  83. Clinical Pig Kidney Xenotransplantation: How Close Are We?
  84. The effect of renal transplantation on left ventricular function, electrocardiography, and mechanical synchrony by gated myocardial perfusion imaging
  85. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial
  86. Tacrolimus troughs and genetic determinants of metabolism in kidney transplant recipients: A comparison of four ancestry groups
  87. WNT pathway signaling is associated with microvascular injury and predicts kidney transplant failure
  88. Analysis of 75 Candidate SNPs Associated With Acute Rejection in Kidney Transplant Recipients: Validation of rs2910164 in MicroRNA MIR146A
  89. Letter to the Editor
  90. Genetic Variants Associated With Immunosuppressant Pharmacokinetics and Adverse Effects in the DeKAF Genomics Genome-wide Association Studies
  91. CYP3A5 genotype affects time to therapeutic tacrolimus level in pediatric kidney transplant recipients
  92. Repeat kidney transplant recipients with active rejection have elevated donor-derived cell-free DNA
  93. Long-term follow-up of the DeKAF cross-sectional cohort study
  94. Application of TruGraf v1: A Novel Molecular Biomarker for Managing Kidney Transplant Recipients With Stable Renal Function
  95. Investigator Assessment of the Utility of the TruGraf Molecular Diagnostic Test in Clinical Practice
  96. The impact of donor and recipient common clinical and genetic variation on estimated glomerular filtration rate in a European renal transplant population
  97. The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: The Transplant Therapeutics Consortium’s position statement
  98. Post-Transplant Lymphoproliferative Disorder in a Kidney Transplant Recipient
  99. Acute Kidney Injury in Kidney Transplants: New Insights
  100. The Banff schema for antibody-mediated rejection: Lost in translation?
  101. Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop
  102. Identification of genetic variants associated with tacrolimus metabolism in kidney transplant recipients by extreme phenotype sampling and next generation sequencing
  103. Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients
  104. Meeting report of the STAR—Sensitization in Transplantation Assessment of Risk: Naïve Abdominal Transplant Organ subgroup focus on kidney transplantation
  105. Author Correction: Metformin reverses established lung fibrosis in a bleomycin model
  106. Establishing a Core Outcome Measure for Graft Health
  107. Thrombotic Microangiopathy in a Transplant Recipient
  108. Metformin reverses established lung fibrosis in a bleomycin model
  109. Subclinical inflammation phenotypes and long-term outcomes after pediatric kidney transplantation
  110. Apolipoprotein L1 and Chronic Kidney Disease Risk in Young Potential Living Kidney Donors
  111. Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report
  112. Late graft failure after kidney transplantation as the consequence of late versus early events
  113. NPHP1(Nephrocystin-1) Gene Deletions Cause Adult-Onset ESRD
  114. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials
  115. Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients
  116. Delayed Graft Function: The AKI of Kidney Transplantation
  117. Genome-wide association study identifies the common variants in CYP3A4 and CYP3A5 responsible for variation in tacrolimus trough concentration in Caucasian kidney transplant recipients
  118. Lessons Learned: Early Termination of a Randomized Trial of Calcineurin Inhibitor and Corticosteroid Avoidance Using Belatacept
  119. Clinical Trials for Immunosuppression in Transplantation
  120. Effect of a Mobile Web App on Kidney Transplant Candidates' Knowledge About Increased Risk Donor Kidneys
  121. Real Time Central Assessment of Kidney Transplant Indication Biopsies by Microarrays: The INTERCOMEX Study
  122. B Cell Receptor Genes Associated With Tolerance Identify a Cohort of Immunosuppressed Patients With Improved Renal Allograft Graft Function
  123. Biological Variation of Donor-Derived Cell-Free DNA in Renal Transplant Recipients: Clinical Implications
  124. Cell-Free DNA and Active Rejection in Kidney Allografts
  125. Obesity increases the risk of end-stage renal disease among living kidney donors
  126. Access to Kidney Transplantation among HIV-Infected Waitlist Candidates
  127. Inpatient Mortality Among Solid Organ Transplant Recipients Hospitalized for Sepsis and Severe Sepsis
  128. Developing New Immunosuppression for the Next Generation of Transplant Recipients: The Path Forward
  129. A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation
  130. Genotype-guided tacrolimus dosing in African-American kidney transplant recipients
  131. Hospital-Onset Clostridium difficile Infection Among Solid Organ Transplant Recipients
  132. Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies MultipleCYP3A5Alleles
  133. Center-Level Experience and Kidney Transplant Outcomes in HIV-Infected Recipients
  134. Genomic and proteomic fingerprints of acute rejection in peripheral blood and urine
  135. The Cost of Transplant Immunosuppressant Therapy: Is This Sustainable?
  136. Identification of Strategies to Facilitate Organ Donation among African Americans using the Nominal Group Technique
  137. Cyclosporine-mediated allograft fibrosis is associated with micro-RNA-21 through AKT signaling
  138. The prognostic value of left ventricular mechanical dyssynchrony using gated myocardial perfusion imaging in patients with end-stage renal disease
  139. Mitigation of Racial Disparities After Simultaneous Pancreas and Kidney Transplantation.
  140. The Microbiota, the Immune System and the Allograft
  141. Immunosuppression Regimen and the Risk of Acute Rejection in HIV-Infected Kidney Transplant Recipients
  142. Banff 2013 Meeting Report: Inclusion of C4d-Negative Antibody-Mediated Rejection and Antibody-Associated Arterial Lesions
  143. Necroptosis in Solid Organ Transplantation: A Missing Link to Immune Activation?
  144. Report of the second joint meeting of ESOT and AST: current pipelines in biotech and pharma
  145. Multicenter evaluation of a standardized protocol for noninvasive gene expression profiling
  146. A reproducible mouse model of chronic allograft nephropathy with vasculopathy
  147. Associations of ABCB1 and IL-10 Genetic Polymorphisms With Sirolimus-Induced Dyslipidemia in Renal Transplant Recipients
  148. A Case of Late Kidney Allograft Failure: A Clinical Pathological Conference from American Society of Nephrology Kidney Week 2011
  149. Reply to “Genetic Determinants of Mycophenolate-Related Anemia and Leukopenia After Transplantation”
  150. Macrophages
  151. Associations of ABCB1 3435C>T and IL-10-1082G>A Polymorphisms With Long-Term Sirolimus Dose Requirements in Renal Transplant Patients
  152. What’s New, What’s Hot in Solid Organ Transplantation? Summary of the American Transplant Congress 2011
  153. Elevated expression levels of ANXA11, integrins β3 and α3, and TNF‐α contribute to a candidate proteomic signature in urine for kidney allograft rejection
  154. Genetic Determinants of Mycophenolate-Related Anemia and Leukopenia After Transplantation
  155. Novel Polymorphisms Associated With Tacrolimus Trough Concentrations: Results From a Multicenter Kidney Transplant Consortium
  156. Chemokines and Their Receptors in Human Renal Allotransplantation
  157. Lack of Renal Dopamine D5 Receptors Promotes Hypertension
  158. Immune monitoring and biomarkers to predict chronic allograft dysfunction
  159. Optimal Cutoff Point for Immunoperoxidase Detection of C4d in the Renal Allograft: Results From a Multicenter Study
  160. Cinacalcet Improves Bone Density in Post–Kidney Transplant Hyperparathyroidism
  161. Inflammation in Areas of Tubular Atrophy in Kidney Allograft Biopsies: A Potent Predictor of Allograft Failure
  162. Probabilistic (Bayesian) Modeling of Gene Expression in Transplant Glomerulopathy
  163. Evidence for Antibody-Mediated Injury as a Major Determinant of Late Kidney Allograft Failure
  164. Evaluation of tacrolimus abbreviated area‐under‐the‐curve monitoring in renal transplant patients who are potientially at risk for adverse events
  165. Low-density array PCR analysis of reperfusion biopsies: an adjunct to histological analysis
  166. Banff ’09 Meeting Report: Antibody Mediated Graft Deterioration and Implementation of Banff Working Groups
  167. Allograft Fibrosis—Unmasking the Players at the Dance
  168. Histopathologic Clusters Differentiate Subgroups Within the Nonspecific Diagnoses of CAN or CR: Preliminary Data from the DeKAF Study
  169. Pathological and Clinical Characterization of the ‘Troubled Transplant’: Data from the DeKAF Study
  170. Noninvasive methods to assess the risk of kidney transplant rejection
  171. C3 Polymorphisms and Outcomes of Renal Allografts
  172. Post-transplantation Monitoring and Outcomes
  173. Islet transplantation: need for a time-out?
  174. Lymphocyte depletion for kidney transplantation: back to the past?
  175. Pharmacokinetics of Low and Maintenance Dose Valganciclovir in Kidney Transplant Recipients
  176. Leflunomide Therapy in Kidney Transplantation
  177. Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions
  178. Therapeutic management of posttransplant diabetes mellitus
  179. Care of the Kidney Transplant Recipient
  180. Late Kidney Allograft Loss
  181. Monocyte Infiltration and Kidney Allograft Dysfunction During Acute Rejection
  182. Obesity following kidney transplantation and steroid avoidance immunosuppression
  183. Diagnostic Tools for Monitoring Kidney Transplant Recipients
  184. Banff ’05 Meeting Report: Differential Diagnosis of Chronic Allograft Injury and Elimination of Chronic Allograft Nephropathy (’CAN’)
  185. Immunodiagnostics: Evaluation of Functional T-Cell Immunocompetence in Whole Blood Independent of Circulating Cell Numbers
  186. Connective Tissue Growth Factor is a Biomarker and Mediator of Kidney Allograft Fibrosis
  187. Assessing Relative Risks of Infection and Rejection: A Meta-analysis using an Immune Function Assay
  188. Autoimmune Thyroid Disease After Renal Transplantation Using Depletional Induction with Alemtuzumab
  189. Beyond Histology
  190. Therapeutic Targets in the Treatment of Allograft Fibrosis
  191. Platelet-derived or soluble CD154 induces vascularized allograft rejection independent of cell-bound CD154
  192. Successful Renal Transplantation in Patients with Chronic Granulomatous Disease
  193. Molecular Evaluation of BK Polyomavirus Nephropathy
  194. Results from a Human Renal Allograft Tolerance Trial Evaluating T-Cell Depletion with Alemtuzumab Combined with Deoxyspergualin
  195. Idiopathic intracranial hypertension following kidney transplantation: A case report and review of the literature
  196. Detection and Localization of Proteinuria by Dynamic Contrast-Enhanced Magnetic Resonance Imaging Using MS325
  197. Surgical transplant physical examination: Correlation of renal resistance index and biopsy-proven chronic allograft nephropathy
  198. Functionally Significant Renal Allograft Rejection Is Defined by Transcriptional Criteria
  199. Immunocompetent T-Cells with a Memory-Like Phenotype are the Dominant Cell Type Following Antibody-Mediated T-Cell Depletion
  200. First NIH/Office of Rare Diseases Conference on Cystinosis: past, present, and future
  201. Strategies for minimizing immunosuppression in kidney transplantation
  202. Donor genomics influence graft events: The effect of donor polymorphisms on acute rejection and chronic allograft nephropathy
  203. The road to tolerance: renal transplant tolerance induction in nonhuman primate studies and clinical trials
  204. POLYOMAVIRUS NEPHROPATHY: WHAT HAVE WE LEARNED?1
  205. The clinical application of monoclonal antibody therapies in renal transplantation
  206. Successful Renal Transplantation in a Patient with Congenital Generalized Lipodystrophy: A Case Report
  207. Immunologic monitoring of the transplant recipient: challenges and approaches with antibody induction
  208. RESULTS FROM A HUMAN RENAL ALLOGRAFT TOLERANCE TRIAL EVALUATING THE HUMANIZED CD52-SPECIFIC MONOCLONAL ANTIBODY ALEMTUZUMAB (CAMPATH-1H)
  209. Delayed autotransplantation of a solitary kidney facilitated by pump perfusion preservation
  210. Inhibition of Prolyl-4-Hydroxylase Ameliorates Chronic Rejection of Mouse Kidney Allografts
  211. Kidney transplantation with rabbit antithymocyte globulin and sirolimus monotherapy
  212. BK virus and SV40 co-infection in polyomavirus nehropathy1
  213. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy
  214. Molecular and immunohistochemical characterization of the onset and resolution of human renal allograft ischemia-reperfusion injury
  215. Absence of donor MHC antigen expression ameliorates chronic kidney allograft rejection
  216. Deficiency of 5-Lipoxygenase Accelerates Renal Allograft Rejection in Mice
  217. Receptors for prostaglandin E2 that regulate cellular immune responses in the mouse
  218. ALTERED INTRAGRAFT IMMUNE RESPONSES AND IMPROVED RENAL FUNCTION IN MHC CLASS II-DEFICIENT MOUSE KIDNEY ALLOGRAFTS12
  219. Stimulation of Thymocyte Proliferation by Phosphorothioate DNA Oligonucleotides
  220. ENHANCED T CELL CYTOKINE GENE EXPRESSION IN MOUSE AIRWAY OBLITERATIVE BRONCHIOLITIS1
  221. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway
  222. Inducible nitric oxide synthase promotes cytokine expression in cardiac allografts but is not required for efficient rejection
  223. Peptide YY/neuropeptide Y Y1 receptor expression in the epithelium and mucosal nerves of the human colon
  224. Gene targeting: Applications in transplantation research
  225. Chronic rejection of mouse kidney allografts
  226. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2.
  227. Immune Cells in a Mouse Airway Model of Obliterative Bronchiolitis
  228. Thromboxane A2modulates the fibrinolytic system in glomerular mesangial cells
  229. Downregulation of T cell receptor expression by CD8(+) lymphocytes in kidney allografts.
  230. Distribution of binding sites for thromboxane A2 in the mouse kidney
  231. THE INTRAGRAFT CD8+ T CELL RESPONSE IN RENAL ALLOGRAFT REJECTION IN THE MOUSE1,2
  232. REJECTION OF KIDNEY ALLOGRAFTS BY MHC CLASS I-DEFICIENT MICE
  233. Hyperrenin-Hyperaldosterone-Dependent Malignant Hypertension in Polyarteritis Nodosa
  234. Alterations In Renal Interleukin-1 Production During Kidney Transplant Rejection In The Rat
  235. Immunologic mechanisms of transplant rejection
  236. Myocardial ischemia in constrictive pericarditis
  237. Role of immune stimulation in the etiology of multiple myeloma: A case control study
  238. A plasma membrane factor inhibiting intercellular adhesion in Polysphondylium pallidum